Bacterial vaginosis is a common vaginal infection, and is classified as a sexually transmitted infection (STI). Bacterial vaginosis occurs when there is a change in the natural balance of bacteria in vagina. Bacterial vaginosis is usually treated with antibiotic tablets or gel. The disease usually occurs in the women in the age group of 15-44. Although, the exact cause of bacterial vaginosis is unknown, it is believed that the infection typically occurs in sexually active women. The disease is linked to an imbalance of “good” and “harmful” bacteria that are normally found in a woman’s vagina. Having a new sex partner or multiple sex partners, as well as douching, can upset the balance of bacteria in the vagina. The imbalance of bacteria in the vagina further increases the risk for getting bacterial vaginosis. Some of the symptoms of the disease include unusual vaginal discharge, burning when urinating and itching around the outside of the vagina. Some of the drug candidates in the pipeline for treating bacterial vaginosis include, but are not limited to, Astodrimer, Rifaximin and Garenoxacin.
Some of the companies having drugs in the bacterial vaginosis pipeline include Alfa Wassermann S.p.A, Starpharma Holdings Limited and Symbiomix Therapeutics, LLC.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.